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Hantaviruses are associated with hemorrhagic
fever with renal syndrome (HFRS) and hantavirus
pulmonary syndrome (HPS) in humans (1). Sin
Nombre virus (SNV), a newly identified
hantavirus, was identified as the causative agent
in a 1993 outbreak of HPS with a >60% case-
fatality rate in the southwestern United States
(2). SNV and other American hantaviruses
associated with HPS have a specific rodent
reservoir; transmission was inferred to occur
primarily by inhalation of infected aerosols from
the rodent urine and excreta (3,4). However, an
outbreak with human-to-human transmission of
HPS caused by Andes virus has also been
reported from South America (5). HPS is
clinically characterized as an acute febrile illness
associated with headache, malaise, and myalgia
that proceeds to thrombocytopenia, pulmonary
edema, and hypotension or shock (1,2). In fatal
cases, death usually occurs 1 to 2 days after onset
of respiratory symptoms. Although SNV-specific
CD4+ and CD8+ T lymphocytes have been
documented (6), the virus-specific humoral
immune response has not yet been well defined.
The different patterns of increase in
immunoglobulin (Ig) classes are associated with
Th1- or Th2-type immune responses in mice (7).
In some parasitic diseases, increased antigen-
specific IgG4 subclass levels correspond to a
variable extent with the induction of antigen-
specific T-cell anergy, sometimes associated with
serious or disseminated disease (8,9). Antibody
responses to polysaccharide antigens have been
reported to be predominantly IgG1/IgG2 (10). In
viral diseases, IgG1 and IgG3 subclasses were
detected predominantly in primary infections,
while IgG2 and IgG4 subclasses were more
characteristic of recurrent infections (11-14).
Ig class- and subclass-specific titers of
antibodies to SNV, their kinetic appearance, and
their role in preventing disease or death in HPS
patients has not been reported. To address this
issue, we developed SNV-specific, immunoglobu-
lin class/subclass-specific enzyme-linked immun-
osorbent assays and evaluated the levels of SNV-
specific IgA, IgM, and IgG subclass antibodies
in the serum samples from HPS patients. Ig
class- and subclass-specific titers were com-
pared in the sera of patients who survived and
those who died.
The Study
Thirty-three serum samples were obtained
from 22 patients hospitalized with HPS in 1993.
Patients were diagnosed as having HPS on the
basis of results from immunohistochemistry
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Serum samples from 22 hantavirus pulmonary syndrome (HPS) patients were tested
for Sin Nombre virus (SNV)-reactive antibodies. In the acute phase of HPS, 100% and
67% of the samples tested positive for SNV-specific immunoglobulin (Ig) M and IgA,
respectively. Among the virus-specific IgG antibodies, the most prevalent were IgG3 (in
97% of samples), followed by IgG1 (70%), IgG2 (30%), and IgG4 (3%).Dispatches
185 Vol. 6, No. 2, March–April 2000 Emerging Infectious Diseases
analysis, alone or in combination with serologic
studies or reverse transcription-polymerase
chain reaction (16). The samples were divided
into three groups with respect to the time of
collection: acute phase (1-8 days
posthospitalization, 12 samples), early convales-
cent phase (9-30 days posthospitalization, 9
samples), and late convalescent phase (31 days to
1.5 years posthospitalization, 12 samples).
Human Ig antibodies were captured by
affinity-purified, polyclonal, monospecific sheep
antihuman IgM, IgG1, IgG2, IgG3, IgG4, and IgA
reactive antibodies (IgM: Biosource, Camarillo,
CA; IgG1, IgG2, IgG3, IgG4, IgA: The Binding
Site, San Diego, CA). The capture antibodies
were coated onto 96-well high-binding microtiter
plates (Corning Costar Corporation, Charlotte,
NC) at 4°C for a minimum of 16 hours (0.5 mg/ml
in 25mM sodium carbonate buffer pH 9.6; 0.1 ml/
well). Sera and detection antibodies were diluted
in PBS, pH 7.4 to 7.6, containing 0.05% Tween 20
supplemented with 4% milk (PBSM). Initially, all
plates were washed and blocked with PBSM for
30 minutes at room temperature. Fourfold
dilutions of the plasma samples in a volume of 0.1
ml were incubated for 1 hour at 37°C, then the
plates were washed and SNV-infected Vero E6
cell slurries (CDC, Atlanta, GA; SPR 268) and
uninfected control slurries (CDC, Atlanta, GA;
SPR 391), diluted 1:10, were added to
appropriate wells. After incubation for 1 hour at
37°C, the plates were washed and incubated with
a polyclonal rabbit anti-SNV serum (CDC,
Atlanta, GA; diluted 1:1000, 0.1 ml/well) as
described. Then the plates were washed and an
alkaline phosphatase-conjugated sheep Ig anti-
rabbit Ig (Southern Biotechnology Associates,
Birmingham, AL) diluted 1:4000 (0.1 ml/well)
was added to each well. After incubation for 1
hour at 37°C, the plates were washed and the
substrate p-nitrophenylphosphate (Bio-Rad, Her-
cules, CA) was added. The reaction was stopped
by the addition of 0.1 ml 0.4 M NaOH, and the
optical density was read at 405 nm.
Where applicable, antibody titers are
presented as geometric mean titers (GMT), with
the range of positive titers. Antibody titers for
significant differences between survivors and
patients  who died in the acute-phase group were
compared by unpaired Student’s t-test.
SNV-specific IgM, which had the highest
titers overall (GMT 15,097, range 1,600-102,400),
was detected in all acute-phase samples and 89%
of samples from the early convalescent phase
(Table). SNV-specific IgM was also detected in
one sample from the late convalescent phase
(titer 25,600 at day 67), a phenomenon
occasionally observed in other HPS convalescent-
phase samples (data not shown). SNV-specific
serum IgA was detected in 67% of acute-phase
samples and 78% of samples from the early
convalescent phase, but the titers were generally
lower (GMT 9,406, range 100 to 409,600) than the
IgM titers. Two of the 12 patients during the late
convalescent phase had detectable virus-specific
IgA, although the titers were relatively low (1,600
and 100). Patients who had very low or
undetectable SNV-specific IgA generally also had
lower titers of SNV-specific IgM during the acute
phase of illness.
In the IgG class, the highest SNV-specific
antibody titers were predominantly of the IgG3
subclass (GMT 4,935, range 100-409,600),
detected in 97% of samples. SNV-specific IgG1
antibodies were also detected in 76% of samples,
but in much lower titers (GMT 447, range 100-
6,400). SNV-specific IgG2 antibodies were detected
in only 30% of samples (GMT 348, range 100-
6,400), and only one serum tested positive for
SNV-specific IgG4, with a very low titer (1:100).
The Ig class- and subclass-specific antibody
titers were further analyzed with regard to the
outcome of the disease. The 12 patients who had
samples drawn during the acute phase of
infection included six who died and six who
survived. The SNV-specific antibody titers of
these two groups did not differ significantly in
any Ig class or subclass tested (p > 0.1 in each Ig
class or IgG subclass group, data not shown).
When total IgG, IgA, and IgM concentrations
were measured in 18 serum samples from
randomly chosen HPS patients, 12% of the IgM
values (reference range 56-332 mg/dl), 39% of the
IgA values (reference range 70-312 mg/dl) and 56%
of the IgG values (reference range 639-1349 mg/dl)
fell outside the normal reference range.
Interestingly, increased titers of both SNV-specific
IgA and IgM did not correlate with patients’
levels of total serum IgA and IgM. This lack of
correlation suggests that the increase of SNV-specific
IgM and IgA antibodies is not due to nonspecific
polyclonal activation of the immune system.
As expected, SNV-specific IgM antibodies are
observed during the initial phase of disease; both
SNV-specific serum IgA and IgM antibodies peaked
early during the acute phase. These levels wereDispatches
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Table. Total Ig concentrations and specific Sin Nombre virus Ig titers in sera from patients with hantavirus pulmonary
syndrome
   Total    Total Total
IgM IgG IgA
Patienta Daysb IgM IgG1 IgG2 IgG3 IgG4 IgA   [mg/dl] [mg/dl] [mg/dl] Phase
7(d)c     1   25,600    400        0     1,600     0   25,600       264 1,000 336 Acute
8(d)     1     1,600        0        0        100     0            0       559   <333 <67 Acute
9(d)     1   25,600    400        0     6,400     0 102,400       295    802 <40 Acute
6.1     2 102,400 6,400    100   25,600     0   25,600       280 1,590 492 Acute
10(d)     2   25,600    100        0        400     0            0       ndd 4,840 234 Acute
5.1     2   25,600    100        0     1,600     0 409,600     1,080    176 342 Acute
21.1     4 102,400    100 6,400 409,600     0            0 409,600    nd  nd Acute
23.1     7   25,600    100    100        400     0   25,600       nd    nd  nd Acute
1.1     7     1,600    400    100     6,400     0        400       142    401 108 Acute
11(d)     7 102,400    100        0        400     0     6,400       nd    nd  nd Acute
23.2     8   25,600        0        0        100     0            0       nd    nd  nd Acute
12(d)     8     6,400        0        0            0     0            0       108   <381 <67 Acute
4.3   10     6,400        0        0     1,600     0   25,600       nd    nd  nd Early  conv.e
2.1   12   25,600 6,400 1,600   25,600     0 409,600       225    508 125 Early conv.
21.2   13 102,400    100 6,400 409,600 100 409,600       nd    nd  nd Early conv.
23.3   13     6,400        0        0        100     0        100       nd    nd  nd Early  conv.
3.1   16     6,400 6,400    100     6,400     0            0       322 1,170 290 Early conv.
1.2   21   25,600 6,400    400   25,600     0            0       nd    nd  nd Early  conv.
4.1   24     1,600        0        0     6,400     0     6,400       nd    nd  nd Early  conv.
13   24            0 6,400        0 102,400     0 102,400       nd    nd  nd Early conv.
14   30     1,600        0        0     1,600     0        100       nd    nd  nd Early  conv.
15   34            0    100        0     6,400     0            0       201 1,400 263 Late conv.
3.2   35            0 6,400        0     6,400     0            0       176 2,110 221 Late conv.
4.2   59            0        0        0     1,600     0     1,600       144 1,310   95 Late conv.
2.2   66            0 1,600    100     6,400     0            0       126 1,140 140 Late conv.
16   66            0    100        0   25,600     0            0         69    977   82 Late  conv.
20.2   67            0    400    100     6,400     0        100       nd    nd  nd Late  conv.
6.2   67   25,600 6,400        0 102,400     0        100       219 1,700 403 Late conv.
17.1   92            0    100        0 102,400     0            0       107 1,000 162 Late conv.
5.2 145            0    100        0     1,600     0            0         78 1,260 288 Late conv.
18 330            0    100        0   25,600     0            0       nd    nd  nd Late  conv.
17.2 330            0    100        0     6,400     0            0       nd    nd  nd Late  conv.
19 547            0    100        0        400     0            0       nd    nd  nd Late  conv.
aDecimal values indicate sequential samples from one patient.
bDays after patient reported to hospital.
c(d) = patient died.
dnd = not done.
econv. = convalescent.
maintained during both the acute and the early
convalescent phases. SNV-specific antibodies of
IgG1 and IgG3 subclasses appeared during the
first 10 days, coinciding with the appearance of
symptoms. However, high titers were main-
tained throughout early (IgG1) or early and late
convalescent phases (IgG3). In 5 (70%) of the 7
samples that tested positive for SNV-specific
IgG2 antibodies, these titers appeared during
the acute and early convalescent phases but
were lost thereafter.
Conclusions
We tested serum and plasma samples from
HPS patients for the presence of IgA and IgM
class and the IgG subclass-specific antibody titers
against one of the SNV antigens. Although the
design of this study is cross sectional, we observed
a characteristic pattern of appearance of specific
Ig classes/subclasses during the course of
infection. In addition, sequential samples from
several patients were included in the study
(represented by the decimal values in the Table)Dispatches
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and the data from these samples show trends
similar to those observed in the composite with
single samples. SNV-specific IgM and IgA
antibodies appeared in high titers predominantly
during the early phases of infection (in 95% and
71% of samples, respectively). In our IgG subclass-
specific assays, most samples contained IgG3 and
IgG1 subclass-specific SNV-reactive titers
throughout illness. The detection of substantial
IgG3 antibody titers early in hospitalization can
be explained by the fact that since infection
occurred several days before onset of illness,
there was sufficient time to allow a switch to the
IgG class to occur. In contrast with other primary
viral infections, a substantial number of samples
showed high titers of SNV antigen-reactive
antibodies belonging to the IgG3 subclass
rather than the IgG1 subclass. It is possible
that in SNV infection, specific sets of cytokines
may be produced that preferentially stimulate
the production of IgG3 subclass antibody.
The similarity in antibody titers between
deceased and surviving patients is an important
observation. Regardless of the eventual outcome
of infection, the sera from patients during
hospitalization with either HPS or HFRS
contained high levels of antibody. Abundant viral
antigens were present within endothelial cells of
the pulmonary microvasculature, as well as
significant levels of CD8+ T-cell infiltrates and
evidence of circulating pro-inflammatory cytokines
in serum. These findings suggest that the disease
is most likely secondary to immunopathologic
mechanisms (6,15,16). Thus, antibodies may well
play an important role in containing the initial
viremic phase of the infection, but T-cell activation
may have an important role in inducing disease.
In addition, there may be epitopes of the virus
antigens that are not detected by the assays used
in the studies reported here and antibodies
against these epitopes may distinguish infected
persons who do or do not become ill. Further
studies to identify differences in the viral epitopes
recognized by sera from patients who died
compared with those who survived, as well as
comparison of antibody functionality, are needed
to address these issues. Finally, anti-SNV IgM
antibodies were detected in 100% of the patients
in the acute phase of the infection in relatively
high titers (1,600 to 102,400). This finding
confirms that the SNV-specific IgM-capture
enzyme immunoassay we describe can be used as
a valuable tool in the early diagnosis of HPS.
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